Eikon Q2 2026 net loss $88.4M, cash $531.2M; EIK1001 DMC selects dose

Eikon Therapeutics, Inc.

Net loss $88.4M vs $105.2M prior year; R&D $75.5M (+9%), G&A $17.9M (-56%).
Cash $531.2M at June 30, 2026; expected to fund operations into H2 2027.
EIK1001 TeLuRide-006 DMC selected single dosing regimen; TeLuRide-008 first patient dosed.
Seven abstracts accepted at ESMO 2026; initial EIK1004 and EIK1005 data to be presented.
Appointed Ma. Fatima Francisco to Board; EIK1006 IND expected by end of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.